HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oren, M. Search for Related Content PubMed PubMed Citation Articles by Oren, M. Social Bookmarking                      What's this?

J Biol Chem, Vol. 274, Issue 51, 36031-36034, December 17, 1999

MINIREVIEW
Regulation of the p53 Tumor Suppressor Protein^*

From the Department of Molecular Cell Biology, The Weizmann Institute, Rehovot 76100, Israel

	INTRODUCTION

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Mutations in the p53 tumor suppressor gene occur in about 50% of all human tumors, making it the most frequent target for genetic alterations in cancer (for recent reviews on p53 see Refs. 1-5). Such mutations probably facilitate carcinogenesis primarily through abrogating the tumor suppressor activities of the wild type p53 protein, although at least some forms of tumor-associated mutant p53 proteins may also contribute overt oncogenic activities (gain of function). Excessive wild type p53 activity gives rise to a variety of cellular outcomes, most notably cell cycle arrest and apoptosis. These cellular effects of wild type p53 can reduce cancer incidence through elimination of cancer-prone cells from the replicative pool. However, such effects might become very undesirable if occurring in a normal, unperturbed cell. p53 activity must therefore be kept under tight control, being unleashed only when a cell accumulates lesions that may otherwise drive it into a cancerous state. The signals and mechanisms that regulate p53 activity, maintaining it at low levels under normal conditions and turning it on in cancer-prone cells, are the subject of this review.

	p53-activating Signals

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Under normal conditions, p53 is most probably latent. Consequently, it does not interfere with cell cycle progression and cell survival. Moreover, p53 knock-out mice appear in most cases to undergo proper development and maturation (6), suggesting that p53 is not essential for the normal performance of cells within the body. However, a variety of conditions can lead to rapid induction of p53 activity (Fig. 1). The common denominator of these conditions is that they represent various types of stress, which are likely to favor the emergence of cancer-bound cells. Such conditions include direct DNA damage (7-9) as well as damage to components involved in the proper handling and segregation of the cellular genetic material (e.g. the mitotic spindle (10)), ribonucleotide depletion (11), hypoxia (12), heat shock (13), and exposure to nitric oxide (NO) (14). Accumulation of genomic aberrations is a key carcinogenic mechanism; the rapid induction of p53 activity in response to genomic damage thus serves to ensure that cells carrying such damage are effectively taken care of. Furthermore, p53 may also contribute, directly or indirectly, to particular DNA repair processes (15, 16). The pivotal role of p53 in maintaining genomic integrity has earned it the nickname "guardian of the genome" (17). In addition, p53 activity is triggered by a variety of oncogenic proteins, including Myc, Ras, adenovirus E1A, and -catenin (18-21), providing a direct link between oncogenic processes and the tumor suppressor action of p53 (see below).

View larger version (32K): [in this window] [in a new window]   Fig. 1.   Signals that activate p53. Activation results in markedly increased overall p53 protein levels and most probably also in qualitative changes in the protein (= increased specific activity).

	Regulation of p53 Gene Expression

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

As described later, induction of the p53 response upon stress occurs largely through alterations in the p53 protein. Changes in the rate of transcription of the p53 gene play a minor role, if any, in such induction. Consequently, the transcriptional regulation of the p53 gene has received very little attention during recent years. This need not imply that the regulation of p53 gene expression is totally irrelevant. In fact, it was observed long ago that p53 mRNA levels rise substantially upon serum stimulation (22). This rise may be because of the presence of binding sites for serum-induced factors in the p53 promoter (23) as well as to the ability of the p53 gene to bind the c-Myc protein and to be transcriptionally stimulated by excess c-Myc (24). The induction of an anti-proliferative gene, p53, by serum and growth factors may at first glance seem paradoxical. However, it does make good sense. Cells undergoing DNA replication and extensive proliferation are at higher risk of acquiring DNA damage and giving rise to multiple cancer-prone progeny than quiescent cells. Induction of higher p53 mRNA levels under such conditions places the cells in a state of anticipation; as long as there is no DNA damage or other stress, p53 remains latent and does not interfere with normal cellular transactions. However, if conditions emerge that call for a p53 response, the presence of higher levels of p53 mRNA ensures that such a response will be rapid and effective.

	Activation of p53 by Post-transcriptional Mechanisms

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Exposure of cells to p53-activating signals can lead within a relatively short time to a marked elevation in p53 protein. To some extent, this can be achieved by increased translation of the p53 mRNA, probably involving relief of a translational repression mechanism operating through the 3'-untranslated region of this mRNA (25). There also exists evidence that p53 itself can inhibit p53 synthesis through binding to its own mRNA (26, 27). Yet, it is generally accepted that the accumulation of active p53 in response to stress occurs mainly through post-translational mechanisms. Pivotal is the increase in the protein half-life of p53. p53 is usually a very labile protein, turning over with a half-life sometimes as short as a few minutes (28). In response to DNA damage and other types of stress, p53 is markedly stabilized (7, 8). A rapid increase in p53 concentration without a need for de novo transcription is particularly advantageous in cells with severely damaged genomes. In addition, there is most probably a qualitative conversion of p53 from latent to active form. The best documented change concerns the sequence-specific DNA binding activity of p53. p53 operates as a gene-specific transcriptional activator, which relies on its ability to bind defined sequence elements within target genes (1-5). The sequence-specific DNA binding activity of p53 is subject to constitutive negative regulation, primarily through its inhibitory C-terminal domain (29-31). Relief of this inhibition upon exposure to stress results in increased DNA binding (32-34) and consequently increased biochemical and biological activity. The transcriptional activity of p53 may also be induced by changes in other regions, e.g. modifications within its N-terminal transactivation domain, enabling a more efficient recruitment of components of the transcription machinery (35). Finally, p53 activation may also involve a change in subcellular localization; whereas latent p53 may often be cytoplasmic, at least during part of the cell cycle (36), exposure to stress results in its accumulation in the nucleus, where it is expected to exert its biochemical activities.

	The p53-Mdm2 Loop

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

A key player in the regulation of p53 is the Mdm2 protein. Mdm2 is the product of an oncogene, whose excess activity facilitates several types of human cancer (for reviews see Refs. 37-39). Mdm2 exhibits a unique relationship with p53. On the one hand, the Mdm2 protein binds to p53 and inactivates it (40-42). The binding occurs right within the p53 transactivation domain, interfering with recruitment of basal transcription machinery components (43, 44). Moreover, Mdm2 can actively repress transcription when tethered to p53 (45). Importantly, Mdm2 binding can also lead to complete elimination of p53 through proteolytic degradation. On the other hand, p53 binds specifically to the mdm2 gene and stimulates its transcription (46, 47). This duality defines a negative feedback loop (Fig. 2), which probably serves to keep p53 in tight check and to terminate the p53 signal once the triggering stress has been effectively dealt with. In some situations, mdm2 transcription is induced later than that of other p53 target genes (48, 49); this may set a time window within which p53 is allowed to exert freely its biochemical and biological effects. The critical importance of the p53-Mdm2 loop is best illustrated by the analysis of mdm2 knock-out mice. Inactivation of the mdm2 gene results in early embryonal lethality, but this is completely prevented by simultaneous inactivation of p53 (50, 51). Conceivably, in the absence of functional Mdm2 protein, p53 becomes strongly deregulated to the extent that its excess activity leads to embryonic death. The other side of the coin is revealed in certain human cancers; excessive Mdm2 expression, achieved through mdm2 gene amplification (52) or other mechanisms (53), can lead to constitutive inhibition of p53 and thereby promote cancer without a need to alter the p53 gene itself. It should be kept in mind, however, that excess Mdm2 can also promote cancer independently of p53 (54, 55).

View larger version (17K): [in this window] [in a new window]   Fig. 2.   The p53-Mdm2 autoregulatory loop. The p53 protein binds to the mdm2 gene and activates its transcription. The resultant Mdm2 protein binds to p53 and blocks its activity.

	Regulation of p53 Protein Degradation

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Much of the activation of p53 is achieved through p53 protein stabilization. This realization has markedly accelerated research on p53 degradation. It is now well established that the rapid demise of p53 is achieved largely through the ubiquitin-proteasome pathway (56), although a role for other proteolytic enzymes such as calpain has also been implied (57). Mdm2 plays a pivotal role here as well. Elevated Mdm2 levels result in rapid p53 degradation, which is dependent on the ability of the two proteins to engage in direct binding (58, 59). Furthermore, interference with p53-Mdm2 binding by monoclonal antibodies or competitor peptides results in a dramatic stabilization and accumulation of p53 in non-stressed cells (60). This strongly argues that the low basal levels of p53 in such cells are due primarily to continuous Mdm2-promoted degradation.

How does Mdm2 promote p53 degradation? When the proteolytic activity of the proteasome is blocked by specific inhibitors, excess Mdm2 augments the accumulation of ubiquitinated forms of p53 (58, 59), suggesting that Mdm2 facilitates p53 ubiquitination. Strong support for this conclusion was provided by showing that Mdm2 can directly function in vitro as a p53-specific E3 ubiquitin-protein ligase, which covalently attaches ubiquitin groups to p53 (61, 62) (Fig. 3A). It remains to be determined whether Mdm2 operates alone in vivo or is part of a larger E3 complex.

View larger version (34K): [in this window] [in a new window]   Fig. 3.   Regulation of p53-mediated p53 degradation. The binding of Mdm2 to p53 promotes the ubiquitination of p53 and its subsequent degradation by the proteasome (A). DNA damage induces covalent modifications of p53 and Mdm2, particularly phosphorylation (indicated by (P)). Phosphorylation within the Mdm2-p53 binding interface can block binding and thereby protect p53 from degradation (B). Phosphorylation of Mdm2 within domain(s) required for its biochemical activity will also block p53 degradation, even if Mdm2-p53 binding is maintained (C). Deregulated oncoproteins induce the synthesis of ARF, which binds to Mdm2 and prevents its action (D). Ub, ubiquitin monomer. N and C denote the amino and carboxyl terminus, respectively, of each protein.

Although Mdm2 emerges as the key regulator of p53 stability, other mechanisms for p53 ubiquitination and degradation also exist. Of particular interest is the possible role of the c-Jun N-terminal kinase (JNK)¹; in vitro and in vivo studies suggest that the binding of JNK to p53 results in ubiquitination and proteolytic removal of p53 (63). The "division of labor" between Mdm2 and JNK is presently unclear; however, there are strong indications that it changes during the cell cycle (63).

	Covalent Modifications of p53

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Rapid post-translational activation of signaling proteins is often achieved through covalent modifications, particularly protein phosphorylation. It was thus conceivable that the rapid stabilization and activation of the p53 protein upon stress also involves stress-induced covalent modifications of p53. Indeed, there is mounting evidence in support of this conjecture. p53 becomes phosphorylated on multiple sites in vivo in response to various types of stress, and many stress-activated kinases can phosphorylate p53 in vitro (reviewed in Refs. 5 and 64-67). A potential outcome of such phosphorylation might be the stabilization of p53 through inhibition of p53 ubiquitination and degradation. The pivotal role of Mdm2 in these processes suggests several likely scenarios. For instance, because degradation requires the binding of Mdm2 to p53 (58, 59), phosphorylation of residues positioned within the binding interface of either protein may interfere with binding and lead to p53 stabilization (Fig. 3B). In the case of p53, several candidate sites within its Mdm2-binding domain have been identified which are modified in response to DNA damage and whose phosphorylation reduces the affinity of p53 for Mdm2 (68-70). Of particular interest are serines 15 and 20 and threonine 18 of human p53, all located within or very close to the Mdm2-binding domain of p53. Serine 15 has been studied particularly closely, as it is the site of p53 phosphorylation by the ATM kinase (71, 72), whose activity is required for p53 stabilization in response to ionizing radiation and some other types of DNA damage (73, 74). It should be noted that although the idea that such phosphorylation events are responsible for p53 stabilization is very attractive, the in vivo relevance of this idea has been challenged recently (75, 76). Hence, the effect of p53 phosphorylation on stability may depend on the intracellular context and particularly on the availability of alternative mechanisms for p53 degradation.

Stabilization of p53 might be achieved by modifying not only p53 but also Mdm2. In a simple scenario, Mdm2 may become phosphorylated in a manner that disrupts its interaction with p53 (Fig. 3B). In fact, a candidate phosphorylation site within Mdm2 has been described (77). Alternatively, phosphorylated Mdm2 may retain p53 binding but become impaired with regard to its E3 ubiquitin ligase activity (Fig. 3C). This may particularly apply to the C-terminal part of Mdm2, known to be required for p53 ubiquitination (61, 78).

Finally, both p53 and Mdm2 may also be subject to other types of modifications. Acetylation of p53, leading to increased DNA binding, has been well documented (33, 79). p53 glycosylation has also been reported, and it too may increase DNA binding (80). The role of covalent modifications in p53 activation by stress remains a very challenging area of research.

In addition to covalent modifications, protein-protein interactions also play a key role in regulating cellular p53 levels and activity. Such interactions and their implications are the subject of numerous studies, and it is impossible to discuss them thoroughly here. The reader is referred to several recent comprehensive reviews (5, 67, 81).

	The ARF Connection

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

The ability of Mdm2 to promote p53 ubiquitination can be modulated not only by covalent modifications but also by the binding of other regulatory proteins. The most vivid and perhaps most important example is provided by the ARF protein. This small protein arises through translation of an alternative reading frame derived from the INK4A tumor suppressor gene (82). Of note, ARF binds to Mdm2 and to a lesser extent also to p53, and this binding prevents Mdm2-mediated p53 proteolysis (83-85), apparently by blocking the E3 ligase activity of Mdm2 (62). The interaction between Mdm2 and ARF is therefore another attractive candidate for modulation by stress signals.

	p53 and Oncogenic Stress

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

Of particular interest is the activation of the p53 response by oncogenic stress, such as the deregulated expression of oncoproteins like adenovirus E1A, Ras, Myc, and -catenin (Fig. 1). Although the importance of this response to tumor suppression is very obvious (Fig. 4A), its biochemical basis has remained unknown until the discovery of ARF and its role in p53 stabilization. Recent work has revealed that excess activity of several oncoproteins leads to massive induction of ARF (86-88). This induction is primarily because of enhanced transcription, at least some of which is mediated through the E2F transcription factor (89). The induced ARF protein then binds to Mdm2, thus preventing p53 ubiquitination and degradation (Fig. 3D). Obviously, the inhibitory effects of p53 are not triggered when Myc or Ras proteins are recruited as part of a properly orchestrated growth response, initiated by the binding of a growth factor to its receptor, or else such cells would not be able to execute a mitogenic response. The question that comes to mind is: how can p53 tell between such "healthy" activation of Ras, Myc, or E2F and one that occurs independently of a proper growth signal and may lead to cancer? One possible difference may lie in the more transient nature of the activation in the first case. However, it is also conceivable that when a cell is exposed to a growth factor, one arm of the response drives the neutralization of p53 concurrently with the activation of Myc, Ras, and E2F by the other arm. Support for this notion comes from the observation that factors such as basic fibroblast growth factor and insulin-like growth factor-1 up-regulate Mdm2 and quench p53 activity (90, 91). This mechanism could also contribute to the anti-apoptotic potency of these factors. In other cases, receptor-generated signals may act downstream of p53 to abolish its cellular effects without impinging on p53 itself.

View larger version (15K): [in this window] [in a new window]   Fig. 4.   The outcome of p53 activation depends on the nature of the triggering signal. Deregulated excessive activity of proteins involved in positive growth regulation (e.g. when oncogenic mutations occur in the corresponding genes) causes p53 accumulation, often in an ARF-dependent manner (A). This induces growth arrest or apoptosis and prevents the propagation of such cancer-prone cells. When these proteins are induced as part of the normal response to growth factors or survival factors, other arms of the this response may restrain the activation of p53 (B). This will allow proliferation to proceed and will avert cell death.

Obviously, p53 can respond to a plethora of stress conditions. This versatility is provided through its intricate regulation, which allows it to collect inputs from very diverse signaling pathways.

	FOOTNOTES

^* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. Work in the author's laboratory is supported in part by Grant RO1 CA-40099 from the National Cancer Institute, by the Israeli Academy of Sciences and Humanities Centers of Excellence Program, the German-Israeli Project Cooperation (DIP), and the Yad Abraham Center for Cancer Diagnostics and Therapy.

	ABBREVIATIONS

The abbreviation used is: JNK, c-Jun N-terminal kinase.

	REFERENCES

TOP INTRODUCTION p53-activating Signals Regulation of p53 Gene... Activation of p53 by... The p53-Mdm2 Loop Regulation of p53 Protein... Covalent Modifications of p53 The ARF Connection p53 and Oncogenic Stress REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. L. Miller, B. Rickards, M. Mashiba, W. Huang, and S. J. Flint The Adenoviral E1B 55-Kilodalton Protein Controls Expression of Immune Response Genes but Not p53-Dependent Transcription J. Virol., April 15, 2009; 83(8): 3591 - 3603. [Abstract] [Full Text] [PDF]

				D. Lau and H. Bading Synaptic Activity-Mediated Suppression of p53 and Induction of Nuclear Calcium-Regulated Neuroprotective Genes Promote Survival through Inhibition of Mitochondrial Permeability Transition J. Neurosci., April 8, 2009; 29(14): 4420 - 4429. [Abstract] [Full Text] [PDF]

				X. Pan, J. Zhao, W.-N. Zhang, H.-Y. Li, R. Mu, T. Zhou, H.-Y. Zhang, W.-L. Gong, M. Yu, J.-H. Man, et al. Induction of SOX4 by DNA damage is critical for p53 stabilization and function PNAS, March 10, 2009; 106(10): 3788 - 3793. [Abstract] [Full Text] [PDF]

				S. N. Kassam and A. J. Rainbow UV-inducible base excision repair of oxidative damaged DNA in human cells Mutagenesis, January 1, 2009; 24(1): 75 - 83. [Abstract] [Full Text] [PDF]

				B. Setzer, D. Lebrecht, and U. A. Walker Pyrimidine Nucleoside Depletion Sensitizes to the Mitochondrial Hepatotoxicity of the Reverse Transcriptase Inhibitor Stavudine Am. J. Pathol., March 1, 2008; 172(3): 681 - 690. [Abstract] [Full Text] [PDF]

				M. Wang, C. Gu, T. Qi, W. Tang, L. Wang, S. Wang, and X. Zeng BAF53 Interacts with p53 and Functions in p53-mediated p21-gene Transcription J. Biochem., November 1, 2007; 142(5): 613 - 620. [Abstract] [Full Text] [PDF]

				T. Kishi, A. Ikeda, R. Nagao, and N. Koyama The SCFCdc4 ubiquitin ligase regulates calcineurin signaling through degradation of phosphorylated Rcn1, an inhibitor of calcineurin PNAS, October 30, 2007; 104(44): 17418 - 17423. [Abstract] [Full Text] [PDF]

				T. Ishii, H. Sootome, A. J. King, M. Suda, N. Noro, K. Yamashita, and T. Noumi A Robust, Target-Driven, Cell-Based Assay for Checkpoint Kinase 1 Inhibitors J Biomol Screen, September 1, 2007; 12(6): 809 - 817. [Abstract] [PDF]

				J. P. Morton, T. Kantidakis, and R. J. White RNA polymerase III transcription is repressed in response to the tumour suppressor ARF Nucleic Acids Res., May 14, 2007; 35(9): 3046 - 3052. [Abstract] [Full Text] [PDF]

				T. K.S. Ku, D. C. Nguyen, M. Karaman, P. Gill, J. G. Hacia, and D. L. Crowe Loss of p53 Expression Correlates with Metastatic Phenotype and Transcriptional Profile in a New Mouse Model of Head and Neck Cancer Mol. Cancer Res., April 1, 2007; 5(4): 351 - 362. [Abstract] [Full Text] [PDF]

				A. Nag, A. Germaniuk-Kurowska, M. Dimri, M. A. Sassack, C. B. Gurumurthy, Q. Gao, G. Dimri, H. Band, and V. Band An Essential Role of Human Ada3 in p53 Acetylation J. Biol. Chem., March 23, 2007; 282(12): 8812 - 8820. [Abstract] [Full Text] [PDF]

				K. H. Limesand, K. L. Schwertfeger, and S. M. Anderson MDM2 Is Required for Suppression of Apoptosis by Activated Akt1 in Salivary Acinar Cells Mol. Cell. Biol., December 1, 2006; 26(23): 8840 - 8856. [Abstract] [Full Text] [PDF]

				A. Laine, I. Topisirovic, D. Zhai, J. C. Reed, K. L. B. Borden, and Z. Ronai Regulation of p53 Localization and Activity by Ubc13 Mol. Cell. Biol., December 1, 2006; 26(23): 8901 - 8913. [Abstract] [Full Text] [PDF]

				W. Oh, E.-W. Lee, Y. H. Sung, M.-R. Yang, J. Ghim, H.-W. Lee, and J. Song Jab1 Induces the Cytoplasmic Localization and Degradation of p53 in Coordination with Hdm2 J. Biol. Chem., June 23, 2006; 281(25): 17457 - 17465. [Abstract] [Full Text] [PDF]

				C. C. Chua, X. Liu, J. Gao, R. C. Hamdy, and B. H. L. Chua Multiple actions of pifithrin-{alpha} on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2606 - H2613. [Abstract] [Full Text] [PDF]

				A. Klochendler-Yeivin, E. Picarsky, and M. Yaniv Increased DNA Damage Sensitivity and Apoptosis in Cells Lacking the Snf5/Ini1 Subunit of the SWI/SNF Chromatin Remodeling Complex. Mol. Cell. Biol., April 1, 2006; 26(7): 2661 - 2674. [Abstract] [Full Text] [PDF]

				Y. Tabakin-Fix, I. Azran, Y. Schavinky-Khrapunsky, O. Levy, and M. Aboud Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications Carcinogenesis, April 1, 2006; 27(4): 673 - 681. [Abstract] [Full Text] [PDF]

				G. Liu and X. Chen DNA Polymerase {eta}, the Product of the Xeroderma Pigmentosum Variant Gene and a Target of p53, Modulates the DNA Damage Checkpoint and p53 Activation Mol. Cell. Biol., February 15, 2006; 26(4): 1398 - 1413. [Abstract] [Full Text] [PDF]

				T. Shibata, K. Iio, Y. Kawai, N. Shibata, M. Kawaguchi, S. Toi, M. Kobayashi, M. Kobayashi, K. Yamamoto, and K. Uchida Identification of a Lipid Peroxidation Product as a Potential Trigger of the p53 Pathway J. Biol. Chem., January 13, 2006; 281(2): 1196 - 1204. [Abstract] [Full Text] [PDF]

				X. Wang, H.-Y. Kua, Y. Hu, K. Guo, Q. Zeng, Q. Wu, H.-H. Ng, G. Karsenty, B. de Crombrugghe, J. Yeh, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling J. Cell Biol., January 3, 2006; 172(1): 115 - 125. [Abstract] [Full Text] [PDF]

				M. I. Walton, S. C. Wilson, I. R. Hardcastle, A. R. Mirza, and P. Workman An evaluation of the ability of pifithrin-{alpha} and -{beta} to inhibit p53 function in two wild-type p53 human tumor cell lines Mol. Cancer Ther., September 1, 2005; 4(9): 1369 - 1377. [Abstract] [Full Text] [PDF]

				T. Wada, J. W. Pippin, C. B. Marshall, S. V. Griffin, and S. J. Shankland Dexamethasone Prevents Podocyte Apoptosis Induced by Puromycin Aminonucleoside: Role of p53 and Bcl-2-Related Family Proteins J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2615 - 2625. [Abstract] [Full Text] [PDF]

				A. Mueller, B. W. Schafer, S. Ferrari, M. Weibel, M. Makek, M. Hochli, and C. W. Heizmann The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity J. Biol. Chem., August 12, 2005; 280(32): 29186 - 29193. [Abstract] [Full Text] [PDF]

				J. Kwon, K. Mochida, Y.-L. Wang, S. Sekiguchi, T. Sankai, S. Aoki, A. Ogura, Y. Yoshikawa, and K. Wada Ubiquitin C-Terminal Hydrolase L-1 Is Essential for the Early Apoptotic Wave of Germinal Cells and for Sperm Quality Control During Spermatogenesis Biol Reprod, July 1, 2005; 73(1): 29 - 35. [Abstract] [Full Text] [PDF]

				V. Carloni, F. Vizzutti, and P. Pantaleo Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent Clin. Cancer Res., June 1, 2005; 11(11): 4266 - 4274. [Abstract] [Full Text] [PDF]

				M. Riewald and W. Ruf Protease-activated Receptor-1 Signaling by Activated Protein C in Cytokine-perturbed Endothelial Cells Is Distinct from Thrombin Signaling J. Biol. Chem., May 20, 2005; 280(20): 19808 - 19814. [Abstract] [Full Text] [PDF]

				G. Gadea, L. Roger, C. Anguille, M. de Toledo, V. Gire, and P. Roux TNF{alpha} induces sequential activation of Cdc42- and p38/p53-dependent pathways that antagonistically regulate filopodia formation J. Cell Sci., December 15, 2004; 117(26): 6355 - 6364. [Abstract] [Full Text] [PDF]

				V. Calabro, G. Mansueto, R. Santoro, A. Gentilella, A. Pollice, P. Ghioni, L. Guerrini, and G. La Mantia Inhibition of p63 Transcriptional Activity by p14ARF: Functional and Physical Link between Human ARF Tumor Suppressor and a Member of the p53 Family Mol. Cell. Biol., October 1, 2004; 24(19): 8529 - 8540. [Abstract] [Full Text] [PDF]

				J. Kwon, Y.-L. Wang, R. Setsuie, S. Sekiguchi, Y. Sato, M. Sakurai, M. Noda, S. Aoki, Y. Yoshikawa, and K. Wada Two Closely Related Ubiquitin C-Terminal Hydrolase Isozymes Function as Reciprocal Modulators of Germ Cell Apoptosis in Cryptorchid Testis Am. J. Pathol., October 1, 2004; 165(4): 1367 - 1374. [Abstract] [Full Text] [PDF]

				R. Hazan, B. Sat, and H. Engelberg-Kulka Escherichia coli mazEF-Mediated Cell Death Is Triggered by Various Stressful Conditions J. Bacteriol., June 1, 2004; 186(11): 3663 - 3669. [Abstract] [Full Text] [PDF]

				N. Yahagi, H. Shimano, T. Matsuzaka, M. Sekiya, Y. Najima, S. Okazaki, H. Okazaki, Y. Tamura, Y. Iizuka, N. Inoue, et al. p53 Involvement in the Pathogenesis of Fatty Liver Disease J. Biol. Chem., May 14, 2004; 279(20): 20571 - 20575. [Abstract] [Full Text] [PDF]

				F. Schwartzenberg-Bar-Yoseph, M. Armoni, and E. Karnieli The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression Cancer Res., April 1, 2004; 64(7): 2627 - 2633. [Abstract] [Full Text] [PDF]

				F. Mancini, F. Gentiletti, M. D'Angelo, S. Giglio, S. Nanni, C. D'Angelo, A. Farsetti, G. Citro, A. Sacchi, A. Pontecorvi, et al. MDM4 (MDMX) Overexpression Enhances Stabilization of Stress-induced p53 and Promotes Apoptosis J. Biol. Chem., February 27, 2004; 279(9): 8169 - 8180. [Abstract] [Full Text] [PDF]

				T. Itoh, C. O'Shea, and S. Linn Impaired Regulation of Tumor Suppressor p53 Caused by Mutations in the Xeroderma Pigmentosum DDB2 Gene: Mutual Regulatory Interactions between p48DDB2 and p53 Mol. Cell. Biol., November 1, 2003; 23(21): 7540 - 7553. [Abstract] [Full Text] [PDF]

				G. Blander, R. M. de Oliveira, C. M. Conboy, M. Haigis, and L. Guarente Superoxide Dismutase 1 Knock-down Induces Senescence in Human Fibroblasts J. Biol. Chem., October 3, 2003; 278(40): 38966 - 38969. [Abstract] [Full Text] [PDF]

				J. Yu, S. Marsh, R. Ahluwalia, and H. L. McLeod Ferredoxin Reductase: Pharmacogenomic Assessment in Colorectal Cancer Cancer Res., October 1, 2003; 63(19): 6170 - 6173. [Abstract] [Full Text] [PDF]

				H. Kawai, D. Wiederschain, and Z.-M. Yuan Critical Contribution of the MDM2 Acidic Domain to p53 Ubiquitination Mol. Cell. Biol., July 15, 2003; 23(14): 4939 - 4947. [Abstract] [Full Text] [PDF]

				N. Yahagi, H. Shimano, T. Matsuzaka, Y. Najima, M. Sekiya, Y. Nakagawa, T. Ide, S. Tomita, H. Okazaki, Y. Tamura, et al. p53 Activation in Adipocytes of Obese Mice J. Biol. Chem., July 3, 2003; 278(28): 25395 - 25400. [Abstract] [Full Text] [PDF]

				P. Coulombe, G. Rodier, S. Pelletier, J. Pellerin, and S. Meloche Rapid Turnover of Extracellular Signal-Regulated Kinase 3 by the Ubiquitin-Proteasome Pathway Defines a Novel Paradigm of Mitogen-Activated Protein Kinase Regulation during Cellular Differentiation Mol. Cell. Biol., July 1, 2003; 23(13): 4542 - 4558. [Abstract] [Full Text] [PDF]

				J. Thiery, G. Dorothee, H. Haddada, H. Echchakir, C. Richon, R. Stancou, I. Vergnon, J. Benard, F. Mami-Chouaib, and S. Chouaib Potentiation of a Tumor Cell Susceptibility to Autologous CTL Killing by Restoration of Wild-Type p53 Function J. Immunol., June 15, 2003; 170(12): 5919 - 5926. [Abstract] [Full Text] [PDF]

				Y. YANG and X. YU Regulation of apoptosis: the ubiquitous way FASEB J, May 1, 2003; 17(8): 790 - 799. [Abstract] [Full Text] [PDF]

				G. Lagger, A. Doetzlhofer, B. Schuettengruber, E. Haidweger, E. Simboeck, J. Tischler, S. Chiocca, G. Suske, H. Rotheneder, E. Wintersberger, et al. The Tumor Suppressor p53 and Histone Deacetylase 1 Are Antagonistic Regulators of the Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 Gene Mol. Cell. Biol., April 15, 2003; 23(8): 2669 - 2679. [Abstract] [Full Text] [PDF]

				U. G. B. Haider, D. Sorescu, K. K. Griendling, A. M. Vollmar, and V. M. Dirsch Resveratrol Increases Serine15-Phosphorylated but Transcriptionally Impaired p53 and Induces a Reversible DNA Replication Block in Serum-Activated Vascular Smooth Muscle Cells Mol. Pharmacol., April 1, 2003; 63(4): 925 - 932. [Abstract] [Full Text] [PDF]

				G. Urban, T. Golden, I. V. Aragon, L. Cowsert, S. R. Cooper, N. M. Dean, and R. E. Honkanen Identification of a Functional Link for the p53 Tumor Suppressor Protein in Dexamethasone-induced Growth Suppression J. Biol. Chem., March 7, 2003; 278(11): 9747 - 9753. [Abstract] [Full Text] [PDF]

				Y.-H. Ling, L. Liebes, J.-D. Jiang, J. F. Holland, P. J. Elliott, J. Adams, F. M. Muggia, and R. Perez-Soler Mechanisms of Proteasome Inhibitor PS-341-induced G2-M-Phase Arrest and Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines Clin. Cancer Res., March 1, 2003; 9(3): 1145 - 1154. [Abstract] [Full Text] [PDF]

				A. Ben-Yehudah, R. Aqeilan, D. Robashkevich, and H. Lorberboum-Galski Using Apoptosis for Targeted Cancer Therapy by a New Gonadotropin Releasing Hormone-DNA Fragmentation Factor 40 Chimeric Protein Clin. Cancer Res., March 1, 2003; 9(3): 1179 - 1190. [Abstract] [Full Text] [PDF]

				M. A. McCoy, J. J. Gesell, M. M. Senior, and D. F. Wyss Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation PNAS, February 18, 2003; 100(4): 1645 - 1648. [Abstract] [Full Text] [PDF]

				J. Yu, Z. Wang, K. W. Kinzler, B. Vogelstein, and L. Zhang PUMA mediates the apoptotic response to p53 in colorectal cancer cells PNAS, February 18, 2003; 100(4): 1931 - 1936. [Abstract] [Full Text] [PDF]

				A. Wang, J. Gu, K. Judson-Kremer, K.L. Powell, H. Mistry, P. Simhambhatla, C. M. Aldaz, S. Gaddis, and M. C. MacLeod Response of human mammary epithelial cells to DNA damage induced by BPDE: involvement of novel regulatory pathways Carcinogenesis, February 1, 2003; 24(2): 225 - 234. [Abstract] [Full Text] [PDF]

				K. J. Kelly, Z. Plotkin, S. L. Vulgamott, and P. C. Dagher P53 Mediates the Apoptotic Response to GTP Depletion after Renal Ischemia-Reperfusion: Protective Role of a p53 Inhibitor J. Am. Soc. Nephrol., January 1, 2003; 14(1): 128 - 138. [Abstract] [Full Text] [PDF]

				A. Mazzocca, S. Giusti, A. D. Hamilton, S. M. Sebti, P. Pantaleo, and V. Carloni Growth Inhibition by the Farnesyltransferase Inhibitor FTI-277 Involves Bcl-2 Expression and Defective Association with Raf-1 in Liver Cancer Cell Lines Mol. Pharmacol., January 1, 2003; 63(1): 159 - 166. [Abstract] [Full Text] [PDF]

				A. Inga, F. Storici, T. A. Darden, and M. A. Resnick Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence Mol. Cell. Biol., December 15, 2002; 22(24): 8612 - 8625. [Abstract] [Full Text] [PDF]

				M. H. Wu and B. Y. M. Yung UV Stimulation of Nucleophosmin/B23 Expression Is an Immediate-early Gene Response Induced by Damaged DNA J. Biol. Chem., December 6, 2002; 277(50): 48234 - 48240. [Abstract] [Full Text] [PDF]

				Z. Lai, T. Yang, Y. B. Kim, T. M. Sielecki, M. A. Diamond, P. Strack, M. Rolfe, M. Caligiuri, P. A. Benfield, K. R. Auger, et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors PNAS, November 12, 2002; 99(23): 14734 - 14739. [Abstract] [Full Text] [PDF]

				G. Fontemaggi, I. Kela, N. Amariglio, G. Rechavi, J. Krishnamurthy, S. Strano, A. Sacchi, D. Givol, and G. Blandino Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses J. Biol. Chem., November 1, 2002; 277(45): 43359 - 43368. [Abstract] [Full Text] [PDF]

				Z. Saifudeen, J. Marks, H. Du, and S. S. El-Dahr Spatial repression of PCNA by p53 during kidney development Am J Physiol Renal Physiol, October 1, 2002; 283(4): F727 - F733. [Abstract] [Full Text] [PDF]

				D. Javelaud and F. Besancon Inactivation of p21WAF1Sensitizes Cells to Apoptosis via an Increase of Both p14ARF and p53 Levels and an Alteration of the Bax/Bcl-2 Ratio J. Biol. Chem., September 27, 2002; 277(40): 37949 - 37954. [Abstract] [Full Text] [PDF]

				C. Blattner, T. Hay, D. W. Meek, and D. P. Lane Hypophosphorylation of Mdm2 Augments p53 Stability Mol. Cell. Biol., September 1, 2002; 22(17): 6170 - 6182. [Abstract] [Full Text] [PDF]

				S.-J. Kim, S.-G. Hwang, D. Y. Shin, S.-S. Kang, and J.-S. Chun p38 Kinase Regulates Nitric Oxide-induced Apoptosis of Articular Chondrocytes by Accumulating p53 via NFkappa B-dependent Transcription and Stabilization by Serine 15 Phosphorylation J. Biol. Chem., August 30, 2002; 277(36): 33501 - 33508. [Abstract] [Full Text] [PDF]

				Q. Yang, R. Zhang, X. W. Wang, E. A. Spillare, S. P. Linke, D. Subramanian, J. D. Griffith, J. L. Li, I. D. Hickson, J. C. Shen, et al. The Processing of Holliday Junctions by BLM and WRN Helicases Is Regulated by p53 J. Biol. Chem., August 23, 2002; 277(35): 31980 - 31987. [Abstract] [Full Text] [PDF]

				Y. Daniely, D. D. Dimitrova, and J. A. Borowiec Stress-Dependent Nucleolin Mobilization Mediated by p53-Nucleolin Complex Formation Mol. Cell. Biol., August 15, 2002; 22(16): 6014 - 6022. [Abstract] [Full Text] [PDF]

				H. Shimizu, L. R. Burch, A. J. Smith, D. Dornan, M. Wallace, K. L. Ball, and T. R. Hupp The Conformationally Flexible S9-S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo J. Biol. Chem., August 2, 2002; 277(32): 28446 - 28458. [Abstract] [Full Text] [PDF]

				C. L. Johnson, D. Lu, J. Huang, and A. Basu Regulation of p53 Stabilization by DNA Damage and Protein Kinase C Mol. Cancer Ther., August 1, 2002; 1(10): 861 - 867. [Abstract] [Full Text] [PDF]

				S. A. Wood Dubble or Nothing? Is HAUSP Deubiquitylating Enzyme the Final Arbiter of p53 Levels? Sci. Signal., July 30, 2002; 2002(143): pe34 - pe34. [Abstract] [Full Text] [PDF]

				J.-C. Bourdon, J. Renzing, P.L. Robertson, K.N. Fernandes, and D.P. Lane Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane J. Cell Biol., July 22, 2002; 158(2): 235 - 246. [Abstract] [Full Text] [PDF]

				J. G. Rheinwald, W. C. Hahn, M. R. Ramsey, J. Y. Wu, Z. Guo, H. Tsao, M. De Luca, C. Catricala, and K. M. O'Toole A Two-Stage, p16INK4A- and p53-Dependent Keratinocyte Senescence Mechanism That Limits Replicative Potential Independent of Telomere Status Mol. Cell. Biol., July 15, 2002; 22(14): 5157 - 5172. [Abstract] [Full Text] [PDF]

				I. Osman, E. Sherman, B. Singh, E. Venkatraman, M. Zelefsky, G. Bosl, H. Scher, J. Shah, A. Shaha, D. Kraus, et al. Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent J. Clin. Oncol., July 1, 2002; 20(13): 2980 - 2987. [Abstract] [Full Text] [PDF]

				G. Romeo, W.-H. Liu, V. Asnaghi, T. S. Kern, and M. Lorenzi Activation of Nuclear Factor-{kappa}B Induced by Diabetes and High Glucose Regulates a Proapoptotic Program in Retinal Pericytes Diabetes, July 1, 2002; 51(7): 2241 - 2248. [Abstract] [Full Text] [PDF]

				R. Pokroy, Y. Tendler, A. Pollack, O. Zinder, and G. Weisinger p53 Expression in the Normal Murine Eye Invest. Ophthalmol. Vis. Sci., June 1, 2002; 43(6): 1736 - 1741. [Abstract] [Full Text] [PDF]

				C. CROCHEMORE, T. M. MICHAELIDIS, D. FISCHER, J.-P. LOEFFLER, and O. F. X. ALMEIDA Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation FASEB J, June 1, 2002; 16(8): 761 - 770. [Abstract] [Full Text] [PDF]

				X. Wang, D. Michael, G. de Murcia, and M. Oren p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2 J. Biol. Chem., May 3, 2002; 277(18): 15697 - 15702. [Abstract] [Full Text] [PDF]

				R. A. Levine, T. Forest, and C. Smith Tumor Suppressor PTEN is Mutated in Canine Osteosarcoma Cell Lines and Tumors Vet. Pathol., May 1, 2002; 39(3): 372 - 378. [Abstract] [Full Text] [PDF]

				C. Melle and H.-P. Nasheuer Physical and functional interactions of the tumor suppressor protein p53 and DNA polymerase {alpha}-primase Nucleic Acids Res., April 1, 2002; 30(7): 1493 - 1499. [Abstract] [Full Text] [PDF]

				L. Del Valle, S. Delbue, J. Gordon, S. Enam, S. Croul, P. Ferrante, and K. Khalili Expression of JC virus T-antigen in a patient with MS and glioblastoma multiforme Neurology, March 26, 2002; 58(6): 895 - 900. [Abstract] [Full Text] [PDF]

				G. Asher, J. Lotem, R. Kama, L. Sachs, and Y. Shaul NQO1 stabilizes p53 through a distinct pathway PNAS, February 20, 2002; (2002) 52706799. [Abstract] [Full Text] [PDF]

				U. Mayr, M. Mayr, C. Li, F. Wernig, H. Dietrich, Y. Hu, and Q. Xu Loss of p53 Accelerates Neointimal Lesions of Vein Bypass Grafts in Mice Circ. Res., February 8, 2002; 90(2): 197 - 204. [Abstract] [Full Text] [PDF]

				K. Tajima, K. Hosokawa, Y. Yoshida, A. Dantes, R. Sasson, F. Kotsuji, and A. Amsterdam Establishment of FSH-responsive cell lines by transfection of pre-ovulatory human granulosa cells with mutated p53 (p53val135) and Ha-ras genes Mol. Hum. Reprod., January 1, 2002; 8(1): 48 - 57. [Abstract] [Full Text] [PDF]

				E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev Down-Regulation of {beta}-Catenin by Activated p53 Mol. Cell. Biol., October 15, 2001; 21(20): 6768 - 6781. [Abstract] [Full Text] [PDF]

				A. W. Goetz, H. van der Kuip, R. Maya, M. Oren, and W. E. Aulitzky Requirement for Mdm2 in the Survival Effects of Bcr-Abl and Interleukin 3 in Hematopoietic Cells Cancer Res., October 1, 2001; 61(20): 7635 - 7641. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, P. Mitlianga, J. Fueyo, H.-Y. Lee, M. Hu, K. B. Spurgers, T. L. Glass, D. Koul, T.-J. Liu, T. J. McDonnell, et al. Transfer of E2F-1 to Human Glioma Cells Results in Transcriptional Up-Regulation of Bcl-2 Cancer Res., September 1, 2001; 61(18): 6693 - 6697. [Abstract] [Full Text] [PDF]

				N. Dmitrieva, L. Michea, and M. Burg p53 Protects renal inner medullary cells from hypertonic stress by restricting DNA replication Am J Physiol Renal Physiol, September 1, 2001; 281(3): F522 - F530. [Abstract] [Full Text] [PDF]

				K. Suzuki, S. Kodama, and M. Watanabe Extremely Low-Dose Ionizing Radiation Causes Activation of Mitogen-activated Protein Kinase Pathway and Enhances Proliferation of Normal Human Diploid Cells Cancer Res., July 1, 2001; 61(14): 5396 - 5401. [Abstract] [Full Text] [PDF]

				J. T. Zilfou, W. H. Hoffman, M. Sank, D. L. George, and M. Murphy The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation Mol. Cell. Biol., June 15, 2001; 21(12): 3974 - 3985. [Abstract] [Full Text]

				Y. Zhang and Y. Xiong A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation Science, June 8, 2001; 292(5523): 1910 - 1915. [Abstract] [Full Text] [PDF]

				D. Qiao, S. V. Gaitonde, W. Qi, and J. D. Martinez Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation Carcinogenesis, June 1, 2001; 22(6): 957 - 964. [Abstract] [Full Text] [PDF]

				N. Almog, M. Milyavsky, P. Stambolsky, A. Falcovitz, N. Goldfinger, and V. Rotter The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop Carcinogenesis, May 1, 2001; 22(5): 779 - 785. [Abstract] [Full Text] [PDF]

				R. Maya, M. Balass, S.-T. Kim, D. Shkedy, J.-F. M. Leal, O. Shifman, M. Moas, T. Buschmann, Z.'e. Ronai, Y. Shiloh, et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage Genes & Dev., May 1, 2001; 15(9): 1067 - 1077. [Abstract] [Full Text]

				T. Buschmann, O. Potapova, A. Bar-Shira, V. N. Ivanov, S. Y. Fuchs, S. Henderson, V. A. Fried, T. Minamoto, D. Alarcon-Vargas, M. R. Pincus, et al. Jun NH2-Terminal Kinase Phosphorylation of p53 on Thr-81 Is Important for p53 Stabilization and Transcriptional Activities in Response to Stress Mol. Cell. Biol., April 15, 2001; 21(8): 2743 - 2754. [Abstract] [Full Text]

				L. Fajas, C. Paul, A. Vié, S. Estrach, R. Medema, J. M. Blanchard, C. Sardet, and M.-L. Vignais Cyclin A Is a Mediator of p120E4F-Dependent Cell Cycle Arrest in G1 Mol. Cell. Biol., April 15, 2001; 21(8): 2956 - 2966. [Abstract] [Full Text]

				R. Mokdad-Gargouri, K. Belhadj, and A. Gargouri Translational control of human p53 expression in yeast mediated by 5'-UTR-ORF structural interaction Nucleic Acids Res., March 1, 2001; 29(5): 1222 - 1227. [Abstract] [Full Text] [PDF]

				V. Gottifredi, O. Karni-Schmidt, S.-Y. Shieh, and C. Prives p53 Down-Regulates CHK1 through p21 and the Retinoblastoma Protein Mol. Cell. Biol., February 15, 2001; 21(4): 1066 - 1076. [Abstract] [Full Text]

				L. Li, J. Liao, J. Ruland, T. W. Mak, and S. N. Cohen A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control PNAS, February 13, 2001; 98(4): 1619 - 1624. [Abstract] [Full Text] [PDF]

				R. Sasson, K. Tajima, and A. Amsterdam Glucocorticoids Protect against Apoptosis Induced by Serum Deprivation, Cyclic Adenosine 3',5'-Monophosphate and p53 Activation in Immortalized Human Granulosa Cells: Involvement of Bcl-2 Endocrinology, February 1, 2001; 142(2): 802 - 811. [Abstract] [Full Text] [PDF]

				M. Tan, J. Bian, K. Guan, and Y. Sun p53CP is p51/p63, the third member of the p53 gene family: partial purification and characterization Carcinogenesis, February 1, 2001; 22(2): 295 - 300. [Abstract] [Full Text] [PDF]

				B. K. WEAVER, O. ANDO, K. P. KUMAR, and N. C. REICH Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53 FASEB J, February 1, 2001; 15(2): 501 - 515. [Abstract] [Full Text] [PDF]

				A. Hengstermann, L. K. Linares, A. Ciechanover, N. J. Whitaker, and M. Scheffner Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells PNAS, January 23, 2001; (2001) 31470698. [Abstract] [Full Text]

				S. Nakamura, J. A. Roth, and T. Mukhopadhyay Multiple Lysine Mutations in the C-Terminal Domain of p53 Interfere with MDM2-Dependent Protein Degradation and Ubiquitination Mol. Cell. Biol., December 15, 2000; 20(24): 9391 - 9398. [Abstract] [Full Text]

This Article Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oren, M. Search for Related Content PubMed PubMed Citation Articles by Oren, M. Social Bookmarking                      What's this?